Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer

ABSTRACT IMscin001 is a two‐part dose‐finding (Phase Ib) and ‐confirmation (Phase III) study to evaluate atezolizumab pharmacokinetics of subcutaneous (SC) compared with intravenous (IV) administration in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC). The objectives...

Полное описание

Библиографические подробности

Главные авторы:	Phyllis Chan, Stephanie N. Liu, Nathalie Gosselin, Zacharie Sauve, Mathilde Marchand, Alyse Lin, Luis Herraez‐Baranda, James Zanghi, Esther Shearer‐Kang, Xiaoyan Liu, Benjamin Wu, Pascal Chanu
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2025-04-01
Серии:	CPT: Pharmacometrics & Systems Pharmacology
Online-ссылка:	https://doi.org/10.1002/psp4.13310
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!